Glibenclamide

Over the last decade, diabetes mellitus has emerged as an important clinical and public health problem throughout the world. The aim of the study is   perceive the Potentiality of a newer oral Antihyperglycemic combination therapy over conventional therapy in type 2 diabetes. The prospective study was conducted over a period of six months in the department of Medicine, Guntur City Hospital. The prevalence of type2 diabetes was high in male 65.79 % than female 34.21%. Majority of the patients  (23.68 %) belonged to age group of 51–55 years. Majority of patients (55.26%) having a family history of Diabetes. Majority of patients receiving Combination of Glibenclamide + Metformin (60.53%), evaluated for effect on FPG for both combinations. The mean changes in FPG were noted. In the same way effect on HbA1c also noted. Mean changes in for every month HbA1c will be noted. Our study reveals that Combination therapy with Metformin plus Glimepiride is more effective than Glibenclamide plus Metformin; in improving glycemic control in type 2 diabetes, while also allowing a reduction of the dosage of each drug.

In past there have been many medicinal plants, which have been used in traditional medicines for their antidiabetic properties without any scientific support and pharmacological evidence. The present study was undertaken to evaluate the antihyperglycemic activity of the crude extracts of leaves of Holarrhena antidysenterica. The pet ether, chloroform and ethanolic extracts have been subjected to estimate the anti-hyperglycemic activity in alloxan-induced diabetic rats. Blood glucose levels were measured using the commercially available glucometer. Glibenclamide was used as a reference drug at a dose of 0.6 mg/kg. The antioxidant activity of the test samples was studied in the liver tissue of diabetic rats by measuring catalase and lipid peroxidation levels. The results showed that ethanolic extract possessed a significant antihyperglycaemic and antioxidant activity equipotent with the reference drug (glibenclamide), when evaluated in diabetic rats.

The purpose of the present investigation was to enhance the dissolution properties and bioavailability of a poor water soluble drug (Glibenclamide) by matrix-type transdermal films. Eudragit S 100 (Ed S100) and Hydroxypropylmethyl cellulose (HPMC) were used individually or in mixtures to formulate the transdermal devices by solvent casting method. The physicomechanical evaluation of the polymer matrices was performed. The prepared films showed good physicomechanical characteristics as Ed S100 percent increased, where HPMC lowered these characters. In-vitro release studies of ideal films were evaluated and the results revealed that the amount of Glibenclamide released was affected to great extent by the polymer type and also the solvent used. HPMC films showed high release rates of the drug where Ed S100 retards and control the drug release rates. HPMC mixtures with Ed S100 in 1:1 ratio released about 100% of the drug after 6 hours. In vivo evaluation of the prepared films was investigated by testing the hypoglycaemic effects of the drug after transdermal application to diabetic rats. The observed results simulated that obtained after oral administration of Glibenclamide in a dose of 5 mg/kg. The obtained results revealed a good promise of using Glibenclamide via transdermal route which could be of excellent benefit when oral route is unavailable.

  A simple, sensitive and accurate spectrophotometric method was developed in ultraviolet region for the estimation of Glibenclamide in pure drug, pharmaceutical formulation. Linear response obtained was in the concentration range of 5-30µg/ml with correlation coefficient of 0.999 in acetronitrile: 0.2M NaOH (20:80). Excellent recovery proved that the method was sufficiently accurate. There is no interference from any common pharmaceutical additives and diluents. Results of the analysis were validated by recovery studies according to ICH Q2B guidelines. Key words: Glibenclamide, UV- Spectrophotometry, recovery, accuracy.